SS Innovations International, Inc. announced its unaudited financial results for the first quarter ended March 31, 2025, on May 14, 2025. The company reported record quarterly revenue of $5.1 million, representing a 40.8% increase from $3.6 million in the first quarter of 2024.
This revenue growth was primarily driven by higher unit sales of the SSi Mantra 3 surgical robotic system to healthcare facilities in India and internationally. The company also noted an improvement in its gross margin during the quarter, attributed to a reduction in raw material prices.
SS Innovations uplisted to Nasdaq after the quarter end, a move intended to support its global expansion. The company plans to submit a De Novo application for the SSi Mantra to the U.S. Food and Drug Administration by the end of July 2025 for multiple indications, and anticipates European Union CE Mark approval by late 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.